From Technical Validation to Real-World Impact: The HFpEF Case
By Ashley Schmidt VP | GM AHA AI Assessment Lab
Cardiovascular Disease Is Entering Its Precision Era. Trial Design Needs to Catch Up.
By Elliott Green, Co-founder & CEO
Unleashing the Power of Clinical AI: The Dandelion Health Marketplace
By Nick Gossen, Head of Growth
Validating AI for Impact: Tackling Bias for Underrepresented Communities
By Ana Vanessa Ploumpis, VP of Growth Strategy
Measuring GLP-1 Efficacy in the Real World
Does real-world evidence show that GLP-1s are as effective as results reported in randomized controlled clinical trials? Insights from real-world clinical data paint a picture of who responds – and who does not – to GLP-1s outside of clinical trials.
